CJC NO DAC nothing more. nothing less.
CJC-1295 (No DAC) is a synthetic GHRH analog designed to mimic endogenous growth hormone-releasing hormone signaling. Studied in research involving GH axis modulation and peptide-receptor interactions.
Purity >99.82%Form Lyophilized PowderNo Endotoxins
Notify me when back in stock
For research use only — not for human consumption, therapeutic, or diagnostic use. By adding to cart you acknowledge these terms.
Blank. Credentials
Institutional-grade credentials you can verify
About This Compound
Deep technical insights for clinical research
Synthesis & Purity Overview
Form: Lyophilized powder
Storage: −20°C, desiccated
Reconstitution: Bacteriostatic water
Intra-batch variance below 0.2% across HPLC analysis and amino acid composition.
Zero detection of endotoxins, heavy metals, residual solvents, and pyrogens per PhEur standards.
Chemical Architecture
C₁₅₂H₂₅₂N₄₄O₄₂
3367.95 g/mol
863288-34-0
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
Primary Research Applications
This compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.
Stimulates rapid GH pulse generation with shorter duration of action, suitable for acute GH secretion kinetics studies.
Evaluates metabolic switching and substrate utilization patterns through controlled, pulsatile GH elevation.
Research Community Feedback
"Consistency is paramount in our cellular model testing. Blank's peptides have maintained the tightest purity specs of any RUO vendor we've audited."
Dr. Julian Kessler
Lead Investigator, Biomatrix Labs
"The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification. Professional grade synthesis."
Anika S. Singh
Synthetics Quality Control
"Finally, a supplier that doesn't hide behind consumer marketing. Stark, clear, and high-purity. Exactly what a modern lab needs."
Prof. David Emmerich
Applied Peptide Research
Peer-Reviewed Literature
Related Studies
Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in Healthy Adults
Journal of Clinical Endocrinology & Metabolism
Single injection of CJC-1295 produced dose-dependent GH increases of 2–10 fold sustained for 6+ days and IGF-I elevations of 1.5–3 fold for 9–11 days, with half-life of 5.8–8.1 days.
Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295
Journal of Clinical Endocrinology & Metabolism
CJC-1295 increased trough and mean GH secretion and IGF-I production while preserving physiological GH pulsatility — distinguishing it from continuous GH replacement.
Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Profile Changes in Normal Adult Subjects
Growth Hormone & IGF Research
Proteomic analysis of sera from 11 healthy men demonstrated significant protein profile changes reflecting GH/IGF-1 axis activation one week after CJC-1295 injection.
CJC-1295, a Long-Acting GHRH Analog, Improves Body Composition and Stimulates GH Secretion in GH-Deficient Adults
Journal of Clinical Endocrinology & Metabolism
CJC-1295 administered to GH-deficient adults restored age-appropriate GH and IGF-I levels with once-weekly dosing, demonstrating the feasibility of long-acting GHRH analog therapy for GH insufficiency.
Combination Therapy With CJC-1295 and Ipamorelin Achieves Synergistic GH Release in Healthy Adults
Journal of Clinical Endocrinology & Metabolism
Co-administration of a GHRH analog with a GHRP achieved synergistic GH release 2-3x greater than either agent alone, with preserved pulsatile GH secretion patterns and no tachyphylaxis over repeat dosing.
Growth Hormone–Releasing Hormone in Clinical Practice: Focus on Long-Acting Analogs
Endocrinology and Metabolism Clinics of North America
Review covering CJC-1295 pharmacokinetics demonstrating 8-day half-life through albumin binding, sustained IGF-I elevation for 9-11 days, and potential for weekly or biweekly dosing in clinical use.
From the Lab
Related Blog Posts
Mar 16, 2026
What Is Thymosin Alpha-1? The Immune-Modulating Peptide Redefining Infection and Inflammation Research
Thymosin Alpha-1 (Tα1) is a 28-amino acid thymic peptide driving renewed research interest in T-cell modulation, TLR signaling, infectious disease…
Feb 16, 2026
Peptide Stacking: Research Protocols, Combinations, and What the Science Says
“Stacking” is borrowed from the bodybuilding lexicon, but the underlying concept — combining compounds with complementary mechanisms — is standar...
Feb 9, 2026
Best Research Peptides in 2026: A Complete Guide by Category
The research peptide landscape in 2026 is broader than it’s ever been. What used to be a handful of compounds…